Dengvaxia (Dengue vaccine) / Sanofi - LARVOL DELTA

Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis. (PubMed, Infez Med) - "Chimeric Yellow Fever-Dengue Tetravalent Vaccine (CYD-TDV/Dengvaxia®) was assessed in 28 trials, 3 of which reported a pooled vaccine efficacy of 55% (95%CI 47%-62, I 2=86.9%; p <0.001) against Dengue...Takeda-003 (TAK-003/QDENGA®) was evaluated in 23 trials, showing sustained efficacy against virologically confirmed dengue (43.5%-82.1%) and high protection against hospitalization (approximately 87%-90%)...Other promising candidates included other investigational vaccines such as subunit (V180) or DNA-based (TVDV, D1ME100)...Emerging vaccine candidates, including TV003/TV005, Butantan-DV, TDEN, inactivated, subunit, and DNA-based platforms, have also shown promising safety and immunogenicity results in early-phase trials. Future attempts should focus on developing Dengue vaccines that provide safe, balanced, and durable protection against all four Dengue virus serotypes while minimizing the risk of antibody-dependent enhancement, focusing also on special..."

Journal • Retrospective data • Review • Dengue Fever • Infectious Disease

Prevention or Treatment of Dengue Virus Disease: An Update on Recent Vaccination and Therapeutics Globally. (PubMed, Comb Chem High Throughput Screen) - "A holistic approach encompassing vaccination, targeted therapeutics, vector control, diagnostic innovation, and global cooperation is imperative for mitigating the global threat of dengue. Although vaccines are indispensable for disease prevention, new treatment options are essential for directly managing dengue infections."

Journal • Dengue Fever • Hematological Disorders • Infectious Disease

Neutralizing Dengue Antibodies after 10 years of the Chimeric Yellow Fever Tetravalent Dengue Vaccine (CYD-TDV) and Dengue Antibody Cross-reactivity with SARS-CoV-2 in Indonesia. (PubMed, Acta Trop) - "After a decade, CYD-TDV induced higher neutralizing antibody levels significantly for DENV-1, DENV-2, and DENV-4, but not for DENV-3 in adolescents but not in adults. The SARS-CoV-2 neutralizing antibody levels were comparable between groups, However, COVID-19 hospitalizations were more frequent in dengue-vaccinated group."

Journal • Dengue Fever • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Advanced next-generation vaccines for dengue and other flaviviral infections. (PubMed, J Vector Borne Dis) - "The AESOE-guided OE-PCR platform enabled the assembly of synthetic flaviviral DNA fragments of at least 1 kilobase in length from overlapping oligonucleotides, supporting scalable production of synthetic immunogens without the need for infectious viral materials. These live-virus-free strategies may enhance biosafety, reduce development timelines, and improve accessibility for laboratories in resource-limited settings, potentially supporting next-generation vaccine development for dengue and other flaviviral diseases."

Journal • Dengue Fever • Infectious Disease

Dengue and chikungunya vaccines past, present and future: implications for travelers. (PubMed, Curr Opin Infect Dis) - "Dengue and chikungunya vaccines are increasingly being used in immunization programs and pretravel consultations. Further real-world data are needed-particularly for seronegative dengue vaccine recipients and older, immunocompromised or medically at-risk adults. Research priorities include developing single-dose, nonlive dengue vaccines suitable for high-risk groups, understanding long-term chikungunya vaccine performance, and exploring broader flaviviral or pan-arboviral platforms."

Journal • Chikungunya • Dengue Fever • Infectious Disease

CD8+ T cells and Humoral Immunity Influence the Development of Antibody-Dependent Enhancement: Implications for Vaccine Design. (PubMed, bioRxiv) - "ADE complicates dengue vaccine development; signals of ADE were observed in the CYD-TDV (Dengvaxia) vaccine trials but have not yet been reported for trials of TAK-003 (Qdenga)...The model predicts that CD8+ T-cell responses can mitigate ADE-associated pathology and may help explain the differing levels of protection observed for CYD-TDV and TAK-003 vaccines. These findings suggest that evaluating CD8+ T-cell responses alongside antibody titers may be important for assessing vaccine safety and protection."

Journal • Dengue Fever • Infectious Disease • CD8

Inactivated Japanese encephalitis virus vaccination imprints fusion loop-biased antibody responses that are attenuated by repeated live-attenuated dengue vaccination. (PubMed, medRxiv) - "We studied the impact of prior inactivated JEV IXIARO vaccination and simultaneous vaccination on humoral immunity following live-attenuated dengue CYD-TDV vaccination...Importantly, a complete series of live-attenuated dengue vaccine reduced 4G2 FLE bias, encouraged the recruitment of non-fusion-loop epitopes, and lessened FcγRIIa-biased antibody activity. Overall, these results show that vaccination platform, timing, and regimen are critical determinants of epitope dominance and antibody quality following flavivirus vaccination."

Journal • CNS Disorders • Dengue Fever • Infectious Disease

Safety of a tetravalent live dengue virus vaccine in children responding to one serotype only. (PubMed, JCI Insight) - "We propose that individuals with durable NAb to one serotype have an abundance of serotype cross-reactive, non-neutralizing Abs implicated in the enhanced replication of heterologous serotypes. We discuss the implications of our findings for flagging vaccine candidates that are likely to pose a special risk to seronegative subjects."

Journal • Dengue Fever • Infectious Disease

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database. (PubMed, Front Pharmacol) - "CYD-TDV and TAK-003 are the currently licensed live attenuated tetravalent dengue vaccines, differing in serostatus indication, age range, and immunogenic design...This real-world pharmacovigilance study suggests that TAK-003 is predominantly associated with non-serious, reactogenic adverse reactions, whereas CYD-TDV reports more frequently involve serious outcomes, likely reflecting differences in indications and epidemiological contexts. Continued post-marketing surveillance remains essential for both vaccines."

Adverse events • Journal • P4 data • Cardiovascular • Dengue Fever • Gastroenterology • Gastrointestinal Disorder • Hepatology • Infectious Disease

Adverse events following dengue vaccine (Dengvaxia) reported to the Vaccine Adverse Event Reporting System (VAERS), 2019-2025. (PubMed, Vaccine) - No abstract available

Adverse events • Journal • Dengue Fever

Dengue Vaccine Effectiveness: Results from a 6-Year Population-Based Cohort Study in Southern Brazil. (PubMed, Am J Trop Med Hyg) - "Vaccination with at least one dose was associated with approximately a one-third reduction in PDC incidence and a significant reduction in DENV-1 and DENV-4 cases. Despite the VE falling below 50%, vaccination may be justifiable in regions with high disease burden."

Journal • Dengue Fever

Animal Models Illuminate Dengue Immunopathogenesis to Guide Vaccine and Therapeutic Developments. (PubMed, J Virol Methods) - "The protection provided by the monoclonal antibody C10 was shown to mitigate antibody-dependent enhancement (ADE) in murine models, though it is not associated with the Dengvaxia vaccine. The further development of these animal models will be necessary to expedite the safe development of next-generation dengue vaccines (TAK-003, TV003/TV005), antivirals (favipiravir, sofosbuvir), and immune modulators (IL-6 and TNF-α blockers) for use in endemic areas."

Journal • Preclinical • Review • Dengue Fever • Hematological Disorders • Infectious Disease • Obesity • IFNAR2 • IL1B • IL6

Dengue Incidence Following Mass Vaccination: An Interrupted Time Series Study in Paraná, Brazil. (PubMed, Trop Med Infect Dis) - "The campaign was more effective in small municipalities since they had higher vaccination coverage. These findings underscore the significant impact of the vaccination campaign on reducing dengue incidence trends across the targeted municipalities."

Journal • Dengue Fever

Barriers to dengue vaccine coverage in low- and middle-income countries (LMICs). (PubMed, Virology) - "Dengvaxia (CYD-TDV) and Qdenga (TAK-003) are the only two licensed dengue vaccines currently available, while Butantan-DV (TV003) is an advanced candidate with promising Phase 3 clinical trial results...We therefore identify several state and market-driven systemic factors, as well as declining vaccine confidence, as barriers to scaling up dengue vaccine access in LMICs. These barriers must be addressed through creative solutions to ensure the equitable distribution of dengue vaccines to the populations and countries that need them the most."

Journal • Review • Dengue Fever • Infectious Disease

Bridging the knowledge gap: Thai parents' perspectives on dengue infection and its vaccination and the need for targeted promotion. (PubMed, PLoS Negl Trop Dis) - "This study provides insights into Thai parents' understanding of dengue and its vaccine in children. Findings offer a basis for developing targeted public health campaigns and communication strategies to promote dengue vaccine use in children, and to inform public policy on vaccine affordability."

Journal • Dengue Fever • Infectious Disease

Current status of dengue fever epidemics and vaccine development. (PubMed, Virol Sin) - "To date, two vaccines-Dengvaxia and Qdenga-have been licensed for clinical use. Six other vaccine candidates are currently in clinical trials, among which the tetravalent live-attenuated vaccines TV003/TV005 are considered the most promising. Despite considerable advances in dengue vaccine research, significant challenges remain, including the need to elicit balanced immune responses against the four serotypes and to reduce the risk of antibody-dependent enhancement (ADE). Taken together, this review systematically summarizes recent global and regional trends in dengue fever and the current progress in dengue vaccine development, collectively offering a valuable resource for informing prevention and control strategies."

Journal • Review • Dengue Fever • Infectious Disease

Preclinical evaluation of DENV1 mRNA vaccines in mice: Toward improved neutralizing antibody and T cell responses. (PubMed, Biomed Pharmacother) - "Currently, licensed vaccines, Dengvaxia® and Qdenga®, rely on live-attenuated platforms but show limited efficacy due to imbalanced immune responses and risks associated with antibody-dependent enhancement (ADE)...However, the prJEV chimera exhibited low immunogenicity, likely due to prM-E domain incompatibility. Overall, the WT prME construct showed the most favorable balance of immunogenicity and safety, supporting its advancement as a prototype for future tetravalent dengue mRNA vaccine development."

Journal • Preclinical • CNS Disorders • Dengue Fever • Infectious Disease

Optimizing Humoral Immunity for Durable and Broad Protection in Flavivirus Vaccines. (PubMed, Vaccines (Basel)) - "Booster scheduling and baseline serostatus further shape the antibody quality, highlighting the importance of immune imprinting and cross-reactivity in vaccine design. Together, these findings outline the design principles for next-generation flavivirus vaccines, including stabilization of neutralization-sensitive epitopes, use of adjuvants that sustain germinal center responses, optimization of antigen persistence, and tailoring of dosing strategies to immune history to elicit durable and broadly protective humoral immunity."

Journal • Review • CNS Disorders • Dengue Fever • Infectious Disease

Targeting Dendritic Cells with Virus-like Particles: Toward Safer and More Immunogenic Vaccines. (PubMed, Vaccines (Basel)) - "The newer "Qdenga" vaccine offers up to 80% efficacy after a year but provides suboptimal protection against DENV-3 in seronegative individuals... The administration of tetravalent dengue VLP vaccine in BALB/c mice did not result in adverse effects in acute or chronic toxicity evaluations. Therefore, the VLP supports progression toward clinical evaluation, with dendritic cell activation providing additional rationale."

Journal • Dengue Fever • Hematological Disorders

Dengue vaccine effectiveness and safety: a systematic analysis of recent clinical trial data. (PubMed, Virol J) - "This review provides a systematic review of the dengue vaccines data available from the last five years highlighting significant progress in vaccine development, efficacy, and safety and TAK-003 showed the greatest efficacy against hospitalized and symptomatic Dengue patients, reducing risk by 85% (RR 0.15; 95% CI 0.07-0.33)."

Journal • Review • Dengue Fever • Infectious Disease

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial. (PubMed, Hum Vaccin Immunother) - P2 | "None of the participants discontinued the study due to an AE, and no deaths were reported. CYD-TDV demonstrated adequate safety and robust immunogenicity against all dengue serotypes in HIV-positive adults receiving prior antiretroviral treatment."

Journal • P2 data • Dengue Fever • Human Immunodeficiency Virus • Infectious Disease • Pain

Global epidemiology of dengue in paediatric and adolescent populations: a systematic review and meta-analysis. (PubMed, Infect Dis (Lond)) - "Dengue infection affects youth globally across all endemic regions, with similar incidence distribution among continents. These findings illuminate the global and country-specific dengue epidemiology, emphasising the need for enhanced mitigation measures to reduce viral spread and impact."

Journal • Retrospective data • Dengue Fever • Infectious Disease • Pediatrics

Assessing the impact of vaccination against dengue viruses using long-term antibody measurements (ASTMH 2025) - "The results suggest that the vaccine's protection is skewed towards a single dominant serotype, and this protection is of shorter duration compared to natural infection. These preliminary findings align with previous evidence suggesting that Dengvaxia's effectiveness may be limited by immunodominance and interference."

Dengue Fever • Infectious Disease

Challenges in the Prevention and Treatment of Dengue Fever: An Emerging Issue. (PubMed, Am J Trop Med Hyg) - "Existing vaccines, such as Dengvaxia® (Sanofi Pasteur, Paris, France) and Qdenga® (Takeda Pharmaceutical Company, Tokyo, Japan), have demonstrated some efficacy; however, limitations include a lack of efficacy against certain regional DENV strains and the potential for antibody-dependent enhancement (ADE), particularly in individuals without previous DENV exposure...The intricate pathogenesis of DENV, involving complex virus-host interactions and immune responses, presents additional treatment challenges. In this review, the current challenges and advancements in DF prevention and treatment are examined, emphasizing the limits of existing vaccines and medicines while exploring novel approaches with potential for effectiveness in clinical settings."

Journal • Dengue Fever

Structural and energetic basis of marine phytochemicals as dengue NS1 protein inhibitors. (PubMed, Sci Rep) - "It may suppress DENV proliferation. QSAR study suggested that this chemical is anti-viral, although in vivo and in vitro testing is needed."

Journal • Dengue Fever • Infectious Disease